Journal Club 2026

journal club image

Want to Be a Journal Club Presenter or Moderator?

The call for August-December 2026 session speakers and moderators is now open!

Click here to find out more and apply!

Next HOPA Journal Club

Thursday, June 18, 2026 at 12 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Orange button that says click here to register

The moderator for June's Journal Club session is:

Catie Cash, PharmD, BCOP, Clinical Oncology Pharmacist, Adult Bone Marrow Transplant, Duke University Medical Center, Durham, NC

June's Journal Club presenters include:

Gabrielle Carreon, PharmD

carreon(1)

PGY2 Oncology Pharmacy Resident

Hackensack University Medical Center, Hackensack, NJ

Article:

Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

Jessika Patel, PharmD

patel(1)

PGY2 Oncology Pharmacy Resident

Roswell Park Comprehensive Cancer Center
Buffalo, NY

Article:

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Featured Articles

Advocacy

End Cancer Drug Shortages Coalition: A Consensus Statement on Drug Shortages

May 13, 2026

HOPA has spearheaded a multi-year initiative with 16 other organizations to establish the consensus for combating cancer drug shortages. The statement outlines the major factors contributing to this crisis, and recommends policy solutions.

A group of HOPA Annual Conference 2026 attendees gathered around a colorful HOPA sign

Membership

The Good Times Rolled at Record-Breaking HOPA Annual Conference 2026

April 30, 2026

Hosted in New Orleans, the 2026 edition of HOPA's annual gathering totaled 1,785 registrants, topping the event's previous high set just last year.

Advocacy

HOPA Issues Updated Drug Shortages Brief

April 29, 2026

Shortages of drugs that are essential for the treatment and care of individuals with cancer result in compromises to patient care and, ultimately, outcomes.